

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional) A073 U	ON	Application Number 10/061,658
Applicant(s) Philip Gotwals et al.		
Filing Date 01 FEBRUARY 2002	Group Art Unit 1644	

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
O I P E M H J O S B JUL 2 2 2002 P A T E N T T R A D E M A R K O F F I C E	Boerner et al., 1991, J. Immunol., 147:86-95, "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes"
	Border et al., 1994, New England J. Medicine, 331:1286-1292, "Transforming Growth Factor Beta In Tissue Fibrosis"
CE	Bossy et al., 1991, EMBO J., 10:2375-2385, "Characterization of the Integrin Alpha8 subunit: A new integrin beta1-associated subunit, which is prominently expressed on axons and on cells in contact with basal laminae in chick embryos"
CF	Briesewitz et al., 1993, J. of Biol. Chemistry, 268:2989-2996, "Expression of Native and Truncated Forms of the human integrin Alpha1 1 subunit"
CG	Bridges et al., 1995, Mol. Immunol., 32:1329-2989, "Variable Region cDNA Sequences and Characterization of Murine Anti-Human Interferon gamma Receptor Monoclonal Antibodies that Inhibit Receptor Binding By Interferon gamma"
CH	Camper et al., 1998, J. Biol. Chem., 273:20383-20389, "Isolation, Cloning, and Sequence Analysis of the Integrin Subunit alpha10, a Beta1-associated Collagen Binding Integrin Expressed on Chondrocytes"
CI	Cerf-Bensussan et al., 1992, Eur. J. Immunol. 22:273-277, "The human intraepithelial lymphocyte marker HML-1 is an integrin consisting of a Beta7 subunit associated with a distinctive alpha chain"
CJ	Clackson et al., 1991, Nature, 352:624-628, "Making antibody fragments using phage display libraries"
CK	Co et al., 1991, Proc. Natl Acad. Sci., 88:2869-2873, "Humanized antibodies for antiviral therapy"
CL	Colbert et al., 1991, J. of Immunol. Methods, 140: 227-233, "The effect of fluorescein labels on the affinity of antisera to small haptens"
CM	Corbi and Miller et al., 1987, J. of Biol. Chem., 263: 12403-12411, "cDNA cloning and complete primary structure of the alpha subunit of a leukocyte adhesion glycoprotein, p150,95"
M H	Corbi and Kishimoto et al., 1988, J. of Biol. Chem., 263: 12403-12411, "The Human Leukocyte Adhesion Glycoprotein Mac-1 (Complement Receptor Type 3, CD11b) alpha Subunit"
CN	

EXAMINER

Maher Haddad

DATE CONSIDERED

6/3/04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional)

A073 U.

Application Number

10/061,658

Applicant(s)

Philip Gotwals et al.

Filing Date


01 FEBRUARY 2002

Group Art Unit

1644

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MH 	Davies, 1989, J. of Cell Biology, 109: 1817-1826, "The Osteoclast Functional Antigen, Implicated in the Regulation of Bone Resorption, Is Biochemically Related to the Vitronectin Receptor"
CQ	Diamond et al., 1993, 120: 1031-1043, "The I Domain Is a Major Recognition Site on the Leukocyte Integrin Mac-1 (CD-11b/CD18) For Four Distinct Adhesion Ligands"
CR	Edwards et al., 1995, 270:12635-12640, "Identification of Amino Acids In the CD11a I-domain Important for Binding of the Leukocyte Function-associated Antigen-1 (LFA-1) to Intercellular Adhesion Molecules-1 (ICAM-1)*"
CS	Gotwals et al., 1996, J. Clin. Invest., 97:2469-2477, "The <i>alpha1beta1</i> Integrin Is expressed during Neointima Formation in Rat Arteries and Mediates Collagen Matrix Reorganization"
CT	Grayson et al., 1998, J. Exp. Med., 188:2187-2191, "alphadelta2 Integrin Is Expressed on Human Eosinophils and Functions as an Alternative Ligand for Vascular Cell Adhesion Molecule 1 (VCAM-1)"
CU	Hemler et al., 1984, J. of Immunol., 132:3011-3018, "Glycoproteins of 210,000 and 130,000 M.W. On Activated T Cells: Cell Distribution And Antigenic Relation To Components On Resting Cells And T Cell Lines"
CV	Hessle et al., 1984, Differentiation, 26:49-54, "Basement membrane diversity detected by monoclonal antibodies"
CW	Ignatius et al., 1990, J. of Cell Biology, 111:709-720, "Molecular Cloning of the Rat Integrin alpha1 Subunit: A Receptor for Laminin and Collagen"
CX	Kamata et al., 1995, J. of Biological Chem., 270:12531-12535, "Critical Threonine and Aspartic Acid Residues within the I Domains of beta2 Integrins for Interactions with Intercellular Adhesion Molecule 1 (ICAM-1) and C3bi**"
CY	Keely et al., 1995, J. of Cell Science, 108:595-607, "Alteration of collagen-dependent adhesion, motility, and morphogenesis b the expression of antisense alpha2 integrin mRNA in mammary cells"
MH 	Kern et al., 1994, J. of Biol. Chem., 269:22811-22816, "The Role of the I Domain in Ligand Binding of the Human Integrin alpha1beta1"

EXAMINER

Maher Haddad

DATE CONSIDERED

6/3/04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional) A073 U.	Application Number <u>10/061,658</u>
Applicant(s) Philip Gotwal et al.	
Filing Date <u>01 FEBRUARY 2002</u>	Group Art Unit 1644

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
MH <i>mh</i> <i>CPPE</i> <i>JUL 11 2003</i> <i>SEARCHED</i> <i>INDEXED</i> <i>MAILED</i> <i>TRADEMARK</i>	Langholz et al., 1995, J. of Cell Biol., 131:1903-1915, "Collagen and Collagenase Gene Expression in Three-dimensional Collagen Lattices Are Differentially Regulated by alpha1beta1 and alpha2beta1 Integrins"
DB	Larson et al., 1989, J. of Cell Biol., 108:703-712, "Primary Structure of the Leukocyte Function-associated Molecule-1 alpha Subunit: an Integrin with an Embedded Domain Defining a Protein Superfamily"
DC	Lee et al., 1995, Structure, 3:1333-1340, "Two conformations of the integrin A-domain (I-domain): a pathway for activation?"
DD	Lowry et al., 1951, Dept. of Pharma., Washington Univ. School of Med., 265-275, "Protein Measurement with the folin phenol reagent**"
DE	Mendrick et al., 1995, Laboratory Investigation, 72:367-375, "Glomerular Epithelial and Mesangial Cells Differentially Modulate the Binding Specificities of VLA-1 and VLA-2"
DF	Michishita et al., 1993, Cell Press, 72:857-867, "A Novel Divalent Cation-Binding Site in the A Domain of the Beta2 Integrin CR3 (CD11b/CD18) Is Essential for Ligand Binding"
DG	Nagler et al., 1996, Am. J. Respir.Crit. Care Med., 154:1082-1086, "Reduction in Pulmonary Fibrosis <i>In Vivo</i> by Halofuginone"
DH	Nishimura et al., 1994, J. of Biol. Chem., 269:28708-28715, "Integrin-alphaBeta8"
DI	Orlandi, 1989, Proc. Natl. Acad. Sci., 86:3833-3837, "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction"
DJ	Persson et al., 1991, Proc. Natl. Acad. Sci., 88:2432-2436, "Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning"
DK	Pischel et al., 1987, J. of Immunol., 138:226-233, "Use of the monoclonal antibody 12F1 to Characterize the Differentiation Antigen VLA-21"
MH <i>mh</i>	Qu et al., 1995, Proc. Natl. Acad. Sci., 92:10277-10281, "Crystal structure of the I-domain from the CD11a/CD18 (LFA-1, alpha1beta2) integrin"
DL	

EXAMINER

Maher Haddad

DATE CONSIDERED

6/3/04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional) <u>A073 I</u>	ON	Application Number <u>10/061, 658</u>
Applicant(s) Philip Gotwals et al.		
Filing Date <u>01 FEBRUARY 2002</u>	Group Art Unit 1644	

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
<i>MH</i> MIX O I P E JUL 22 2003 P A T E N T & T R A D E M A R K Q U E R Y C E N T E R	Qu et al., 1996, Structure, 4:931-942, "The role of the divalent cation in the structure of the I domain from the CD11a/CD18 integrin"
DO	Queen et al., 1989, Proc. Natl. Acad. Sci., 86:10029-10033, "A humanized antibody that binds to the interleukin 2 receptor"
DP	Riechmann et al., 1988, Nature, 332:323-327, "Reshaping human antibodies for therapy"
DQ	Riikonen et al., 1994, J. of Biol. Chem., 270:376-382, "Transforming Growth Factor-beta Regulates Collagen Gel..."
DR	Schiro et al., 1991, Cell, 67:403-410, "Integrin alpha2beta1 (Ivla-2) Mediates Reorganization and Contraction of Collagen Matrices by Human Cells"
DS	Shaw et al., 1994, J. of Biol. Chem., 269:6016-6025, "Molecular Cloning of the Human Mucosal Lymphocyte Integrin alpha1 Subunit"
DT	Sonnenberg et al., 1987, J. of Biol. Chem., 262:10376-10383, "A Complex of Platelet Glycoproteins Ic and IIa Identified by a Rat Monoclonal Antibody**"
DU	Springer et al., 1990, Nature, 346:425-434, "Adhesion receptors of the immune system"
DV	Stacker et al., 1991, J. of Immunol., 146:648-655, "Leukocyte Integrin P150,95 (CD11c/CD18) Functions..."
DW	Takada et al., 1989, J. of Cell Biol., 109:397-407, "The Primary Structure of the VLA-2/Collagen Receptor alpha2 Subunit.."
<i>MH</i> DX	Tempest et al., 1991, Bio/Tech., 9:266-271, "Reshaping A Human Monoclonal Antibody TO Inhibit Human Respiratory Syncytial Virus Infection <i>In Vivo</i> "

EXAMINER

Maher Habbad


DATE CONSIDERED

6/3/04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance or not considered. Include copy of this form with next communication to applicant.

O I P E JUL 22 2003 PATENT & TRADEMARK OFFICE		Docket Number (Optional), <u>A073</u>	Application Number <u>SON</u> <u>10/061,658</u>
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Applicant(s) <u>Philip Gotwals et al.</u>	
		Filing Date <u>01 FEBRUARY 2002</u>	Group Art Unit <u>1644</u>
*EXAMINER <i>MH</i>	INITIAL <i>MH</i>	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	DY	Van der Vieren et al., 1995, Immunity, 3:683-690, "A Novel Leukointegrin, alphabeta2, Binds Preferentially to ICAM-3"	
	DZ	Verhoeven et al., 1987, Science, 239:1534-1536, "Reshaping Human Antibodies: Grafting an Antilysozyme Activity"	
	EA	Wang et al., 1996, Am. J. Respir. Cell Mol. Biol., 15:664-672, "Differential Regulation of Airway Epithelial Integrins..."	
	EB	Ward et al., 1989, Nature, 341:544-546, "Binding activities of a repertoire of single immunoglobulin variable domains..."	
	EC	Wayner et al., 1988, "J. of Cell Biol., 107:1881-1891, "The Function of Multiple Extracellular Matrix Receptors..."	
	ED	Weinacker et al., 1993, J. of Biol. Chem., 269:6940-6948, "Role of the Integrin alphavbeta6 in Cell Attachment to Fibronectin"	
	EE	Woessner et al., 1961, Arch. of Biochem. and Biophys., 93:440-447, "The Determination of Hydroxyproline in Tissue..."	
	EF	Yao et al., 1996, J. of Cell Science, 109:3139-3150, "Laminins promote the locomotion of skeletal myoblasts..."	
EXAMINER <i>Maker Haddad</i>		DATE CONSIDERED <i>6/3/04</i>	

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance or not considered. Include copy of this form with next communication to applicant.



PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Do not submit a collection of information unless it contains a valid OMB control number.

~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.~~

Substitution of form 1949/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/061,658
Filing Date	February 1, 2002
First Named Inventor	Gotwals, et al.
Art Unit	1644
Examiner Name	Maher Haddad, Ph. D.
Attorney Docket Number	Biogen A073USCont

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
MH		WO97 18838	5/29/97		
		WO97 11718	4/3/97		
		WO9313798	7/22/93		
		WO95 19790	7/27/95		
MH		WO94 17828	9/18/94		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible.⁶ Applicant is to place checkmarks where applicable.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 14-A, TRADEMAKES, 2001 INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		<i>Compl t If Kn. wn</i>	
		Application Number	10/061,658
		Filing Date	February 1, 2002
		First Named Inventor	Gotwals, et al.
		Art Unit	1644
		Examiner Name	Maher Haddad, Ph. D.
Sheet	2	of	2
		Attorney Docket Number	BiogenA073USCont

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
EG	Pappadopoulos, et al., Verh. Dtsch. Ges. Path. 77, 292-295 (1993) (Germany)		
EH	Hakibara, et al., Clin Exp Immunol. 1998; 114: 236-44 (United Kingdom)		
EI	Roy-Chaudhury, et al., Kidney International, Vol. 49 (1996); pp. 127-134 (US)		
EJ	Lin, et al., Current Opinion in Chemical Biology, vol. 2, no. 4, August 1998 (1998-08), pp. 453-457 (DRAFT, 08/08/98)		
EK	Robb, et al., Journal of Clinical Investigation, vol. 94, no. 5, Nov. 1994 (1994-11), pp. 1722-1728 (01/05)		
EL	Robb, et al., European Respiratory Journal, Supplement, vol. 9, no. supp. 22, August 1996 (1996-08) (02/09/97)		

Examiner Signature	Maher Haddad	Date Considered	6/3/04
--------------------	--------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.